1. Home
  2. GBIO vs EQS Comparison

GBIO vs EQS Comparison

Compare GBIO & EQS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GBIO
  • EQS
  • Stock Information
  • Founded
  • GBIO 2016
  • EQS 1991
  • Country
  • GBIO United States
  • EQS United States
  • Employees
  • GBIO N/A
  • EQS N/A
  • Industry
  • GBIO Biotechnology: Pharmaceutical Preparations
  • EQS Finance Companies
  • Sector
  • GBIO Health Care
  • EQS Finance
  • Exchange
  • GBIO Nasdaq
  • EQS Nasdaq
  • Market Cap
  • GBIO 41.2M
  • EQS 33.7M
  • IPO Year
  • GBIO 2020
  • EQS N/A
  • Fundamental
  • Price
  • GBIO $5.19
  • EQS $1.90
  • Analyst Decision
  • GBIO Buy
  • EQS
  • Analyst Count
  • GBIO 4
  • EQS 0
  • Target Price
  • GBIO $10.67
  • EQS N/A
  • AVG Volume (30 Days)
  • GBIO 68.4K
  • EQS 12.1K
  • Earning Date
  • GBIO 11-05-2025
  • EQS 01-01-0001
  • Dividend Yield
  • GBIO N/A
  • EQS N/A
  • EPS Growth
  • GBIO N/A
  • EQS N/A
  • EPS
  • GBIO N/A
  • EQS N/A
  • Revenue
  • GBIO $21,230,000.00
  • EQS $1,355,000.00
  • Revenue This Year
  • GBIO N/A
  • EQS N/A
  • Revenue Next Year
  • GBIO N/A
  • EQS N/A
  • P/E Ratio
  • GBIO N/A
  • EQS N/A
  • Revenue Growth
  • GBIO 61.15
  • EQS 60.35
  • 52 Week Low
  • GBIO $3.00
  • EQS $0.74
  • 52 Week High
  • GBIO $25.70
  • EQS $2.49
  • Technical
  • Relative Strength Index (RSI)
  • GBIO 33.89
  • EQS 45.44
  • Support Level
  • GBIO $5.10
  • EQS $1.75
  • Resistance Level
  • GBIO $6.47
  • EQS $2.01
  • Average True Range (ATR)
  • GBIO 0.24
  • EQS 0.08
  • MACD
  • GBIO -0.12
  • EQS 0.01
  • Stochastic Oscillator
  • GBIO 11.68
  • EQS 49.13

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

About EQS Equus Total Return Inc.

Equus Total Return Inc is a United States-based closed-end management investment company. It invests mainly in companies pursuing growth either through acquisition or organically, leveraged buyouts, management buyouts, and recapitalizations of existing businesses or special situations, and achieves capital appreciation by making investments in equity and equity-oriented securities issued by privately-owned companies or smaller public companies in transactions.

Share on Social Networks: